Genital Herpes Treatment Drugs Market

Herpes is a virus that can cause outbreaks of skin and oral sores. Herpes is caused by the herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2). (HSV-2). HSV-1 causes fever, blisters, and cold sores, whereas HSV-2 causes genital herpes. Acyclovir and valacyclovir are the two approved medications for the treatment of genital herpes. Valacyclovir is a second-line agent, while acyclovir is generally recommended as first-line therapy.

The drivers and restraints of the genital herpes treatment drugs market are increased awareness of the virus and its potential to cause serious health complications; rising demand from diverse end-users across geographies; substantial investments in R&D by key players to develop new treatments and vaccines; and stringent regulations governing product approvals.

The Asia-Pacific region is expected to grow at a compound annual growth rate (CAGR) of **% through 2031. By that year, the global market for drugs to treat genital herpes is expected to reach USD ** billion.

Acelity Therapeutics Inc., Allergan plc, Abbott Laboratories LP, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bayer AG, Boehringer Ingelheim GmbH & Co. KG, Bristol-Myers Squibb Company, Clovis Oncology LLC d/b/a VIVUS, Clovis Oncology LLC d/b/a VIVUS, Clovis Oncology LLC d.